Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | Phase 3 | terminated | May 24, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by DSMB due to futility. | Efficacy / futility |
| NCT04483414 | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer | Phase 2 | withdrawn | Jul 23, 2020 | Dana Mathews | Study was closed since no participants were enrolled. | Enrollment / accrual |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | Phase 1 / Phase 2 | terminated | Apr 13, 2021 | Veru Inc. | Study terminated as end points were not achieved at current dose level. | Other (stated, no rule matched) |
| NCT04658849 | Insulin Resistance Following ADT for Prostate CA | Early Phase 1 | withdrawn | Dec 9, 2020 | St. Louis University | End of grant funding | Funding |
| NCT04077021 | First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Sep 4, 2019 | Calibr, a division of Scripps Research | Business decision | Sponsor / business decision |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent… | Phase 2 | withdrawn | Feb 21, 2023 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Program changed | Other (stated, no rule matched) |
| NCT02968784 | Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined… | N/A | terminated | Nov 21, 2016 | InSightec | Sponsor Decision | Sponsor / business decision |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT03400943 | Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3) | Phase 3 | terminated | Jan 17, 2018 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT04073485 | Microwave Ablation for Uterine Fibroids | N/A | terminated | Aug 29, 2019 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | Phase 1 | withdrawn | May 10, 2021 | Syneos Health | Study abandoned, no participants enrolled | Enrollment / accrual |
| NCT03574194 | Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy | N/A | terminated | Jun 29, 2018 | West Virginia University | Suspended due to COVID-19 pandemic | COVID-19 / pandemic |
| NCT03919214 | Hypertension Management in Cancer Patients | N/A | terminated | Apr 18, 2019 | Duke University | Initially suspended due to Covid-19. After much consideration, it was determined that we do not… | COVID-19 / pandemic |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | Phase 2 | terminated | Aug 22, 2018 | Donna Hammond, PhD | Enrollment challenges | Enrollment / accrual |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate…(CROSSBOW) | Phase 2 | terminated | Sep 11, 2019 | Sir Mortimer B. Davis - Jewish General Hospital | Drug no longer available | Other (stated, no rule matched) |
| NCT03642132 | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | Phase 3 | terminated | Aug 22, 2018 | Pfizer | Phase 3 B9991010 study was stopped due to futility of efficacy at interim analysis on 21Dec2018,… | Efficacy / futility |
| NCT02844647 | Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer | Phase 1 | terminated | Jul 26, 2016 | Sunnybrook Health Sciences Centre | Lack of participants | Other (stated, no rule matched) |
| NCT03440879 | Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose | N/A | terminated | Feb 22, 2018 | Norwegian School of Sport Sciences | Low recruitment rate | Enrollment / accrual |
| NCT04423913 | Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial…(CAPEMCHAR) | Phase 2 | terminated | Jun 9, 2020 | Centre Hospitalier Universitaire de Nīmes | Recruitment difficulties | Enrollment / accrual |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human… | Phase 1 / Phase 2 | terminated | Nov 14, 2014 | Advaxis, Inc. | not stated | Not stated |
| NCT05245435 | Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer | N/A | withdrawn | Feb 18, 2022 | Medical University of Vienna | Recruitment was not possible with the chosen inclusion/exclusion criteria at our Institution. | Enrollment / accrual |
| NCT03122470 | Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate… | N/A | withdrawn | Apr 20, 2017 | Case Comprehensive Cancer Center | PI departure - study not conducted. | Other (stated, no rule matched) |
| NCT01709734 | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate…(ARMOR2) | Phase 2 | terminated | Oct 18, 2012 | LTN PHARMACEUTICALS, INC. | Study was terminated prematurely in all investigational study centers upon recommendation from the… | Efficacy / futility |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice…(ARMOR3-SV) | Phase 3 | terminated | May 8, 2015 | LTN PHARMACEUTICALS, INC. | not stated | Not stated |
| NCT02853604 | Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer(AIM2CERV) | Phase 3 | terminated | Aug 3, 2016 | Advaxis, Inc. | not stated | Not stated |
| NCT03439033 | Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone… | Phase 2 | terminated | Feb 20, 2018 | Weill Medical College of Cornell University | Study Drug was FDA approved Summer 2021 | Other (stated, no rule matched) |
| NCT04797078 | US/MRI Fusion Local Anestesia TransPerineal Prostate Biopsies for Detection of Prostate…(FLAPP) | N/A | withdrawn | Mar 15, 2021 | Karolinska Institutet | Planning halted due to changes in the research group constellation. | Other (stated, no rule matched) |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical… | Phase 3 | terminated | Apr 19, 2019 | Swiss Cancer Institute | Due to lack of funding. | Funding |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | — | withdrawn | Feb 15, 2013 | Global BioClinical | not stated | Not stated |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors… | Phase 2 | withdrawn | Jun 15, 2022 | Haider Mahdi | Slow Accrual | Enrollment / accrual |
| NCT05705700 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | Phase 2 | withdrawn | Jan 31, 2023 | Masonic Cancer Center, University of Minnesota | Feasibility | Other (stated, no rule matched) |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | Phase 3 | terminated | Feb 24, 2023 | Timothy Hoffman | The investigational product was approved by the FDA (12/20/2021) and is now commercially available | Other (stated, no rule matched) |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT04873427 | In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies | — | terminated | May 5, 2021 | Clinica Luganese Moncucco | The results of the genomic analyses were compromised due to the low DNA concentration. | Other (stated, no rule matched) |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Phase 2 | terminated | Mar 29, 2016 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate…(PRIMA) | Phase 2 | terminated | Apr 20, 2015 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT01045226 | Proton Radiation Therapy in Treating Patients With Prostate Cancer | N/A | terminated | Jan 8, 2010 | Abramson Cancer Center at Penn Medicine | participants are no longer being followed up. | Other (stated, no rule matched) |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer)(SHIP) | Phase 2 | terminated | May 26, 2014 | Karyopharm Therapeutics Inc | Due to enrollment challenges. The termination is not a consequence of any safety concern. | Safety / toxicity |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT03796195 | (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes | Phase 4 | terminated | Jan 8, 2019 | Northwestern University | Enrollment issues | Enrollment / accrual |
| NCT03111914 | Applications of Dual Energy CT in Patients With Osseous Metastases From… | N/A | terminated | Apr 13, 2017 | Duke University | Budgetary Issues | Funding |
| NCT04457245 | Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer(PSMA-dRT) | Phase 3 | terminated | Jul 7, 2020 | Jonsson Comprehensive Cancer Center | accrual | Enrollment / accrual |
| NCT03365076 | Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)(EXIPOX) | N/A | terminated | Dec 7, 2017 | University Hospital of North Norway | Slow inclusion rate due to patients operated before intervention is implementable | Other (stated, no rule matched) |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | Phase 1 / Phase 2 | terminated | May 1, 2019 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or…(PALS) | N/A | terminated | May 27, 2015 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
| NCT00849667 | Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and… | Phase 3 | terminated | Feb 24, 2009 | Morphotek | Lack of efficacy | Efficacy / futility |
| NCT02745587 | Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.(PROPER) | Phase 3 | terminated | Apr 20, 2016 | University Hospital, Ghent | Stopped because of poor accrual in June 2021 after the inclusion of 69 patients | Enrollment / accrual |
| NCT02607813 | Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway… | Phase 1 | terminated | Nov 18, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT03987568 | Characterize Tumor Hypoxia by Magnetic Resonance Imaging | N/A | withdrawn | Jun 17, 2019 | Wake Forest University Health Sciences | Issues in reserving MRI scanner | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 22, 2023source: clinicaltrials